[6-K] Prenetics Global Limited Current Report (Foreign Issuer)

Rhea-AI Filing Summary

On 1 Aug 2025, Prenetics Global Limited (NASDAQ: PRE) reported the results of an Extraordinary General Meeting via Form 6-K. Shareholders approved two resolutions:

• Proposal 1 – Authorised Share Capital Increase: the authorised capital rises from US$50,000 (33.3 m shares) to US$320,000 (213.3 m shares) at the unchanged par value of US$0.0015. This adds 160 m Class A shares, 12 m Class B convertible shares and 8 m undesignated shares. The motion passed with 4,250,875 votes FOR versus 503,820 AGAINST (≈78.7% support).
• Proposal 2 – Administrative Filing Authority: authorises the company’s registered office provider to file the amended charter with Cayman authorities. Passed with 4,744,054 FOR and only 14,922 AGAINST.

No financial results were disclosed. Approval materially expands the company’s capacity to issue new equity, signalling potential future capital raises and possible dilution for existing holders.

Positive

• Enhanced financing flexibility: company can raise capital quickly through equity without further shareholder votes, supporting potential growth initiatives or acquisitions.
• Strong shareholder support: 78.7% of votes cast in favour indicates investor confidence in management’s plans.

Negative

• Dilution risk: authorised shares rise from 33.3 m to 213.3 m, paving the way for up to 180 m new shares that could materially dilute existing ownership.
• Lack of stated use of proceeds: no guidance on timing, size or purpose of future issuances heightens uncertainty.
• Possible governance concerns: scale of increase may draw proxy-advisory criticism if used without clear shareholder value justification.

Insights

Equity Analyst

TL;DR: 6x authorised share count enables sizable future equity raises; dilution risk outweighs short-term benefit of balance-sheet flexibility.

The authorised share capital jumps from 33 m to 213 m shares, a >6-fold increase. Management now has headroom to issue up to 180 m additional shares, equal to ~540% of prior authorised shares. While this provides financing flexibility for acquisitions or working-capital needs, it signals a high likelihood of equity issuance, which could pressure the share price and earnings per share. The resolution’s strong 78.7% approval reduces governance friction but does not remove dilution concerns. Lack of accompanying strategic rationale or timetable adds uncertainty, so impact skews negative for existing shareholders.

Corporate Governance Specialist

TL;DR: Governance process followed; overwhelming support legitimises charter change, yet scale of increase is unusually large.

Procedurally, Prenetics complied with Cayman and SEC rules: advance proxy mailing, separate vote tallies for Class A and B, and immediate 6-K disclosure. Both classes supported the measures unanimously or near-unanimously, suggesting alignment between founders (Class B) and public investors. However, increasing authorised capital to >6x original size without stated use of proceeds could raise ISS/Glass Lewis scrutiny in future proxy seasons. Investors should monitor subsequent equity issuance volumes and whether pre-emptive rights or at-market offerings are employed.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE
13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number 001-41401

Prenetics Global Limited

11401 Granite St. Charlotte, NC 28273 USA Unit 703-706, K11 Atelier 728 King’s Road, Quarry Bay Hong Kong

(Addresses of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.  Form 20-F  Form 40-F 

Results of the 2025 Extraordinary General Meeting of Shareholders

On August 1, 2025, Prenetics Global Limited, an exempted company incorporated with limited liability under the laws of the Cayman Islands (the "Company"), held its Extraordinary General Meeting of Shareholders (the "Meeting"), in accordance with its amended and restated memorandum and articles of association. At the Meeting, the Company's shareholders approved the following proposals, which are described in more detail in the Company's proxy statement, mailed to shareholders on or about July 18, 2025:

Proposal No. 1. Authorised Share Capital Increase

To approve by a special resolution, that the Company's authorised share capital be increased from US$50,000 divided into 33,333,334 shares of US$0.0015 par value each, of which (i) 26,666,667 are designated as Class A Ordinary Shares, (ii) 3,333,333 are designated as convertible Class B Ordinary Shares and (iii) 3,333,334 are designated as shares of such class or classes (however designated) as the board of directors may determine in accordance with the amended and restated memorandum and articles of association of the Company, to US$320,000 divided into 213,333,334 shares of US$0.0015 par value each, of which (i) 186,666,667 are designated as Class A Ordinary Shares, (ii) 15,333,333 are designated as convertible Class B Ordinary Shares and (iii) 11,333,334 are designated as shares of such class or classes (however designated) as the board of directors may determine in accordance with the amended and restated memorandum and articles of association of the Company, by the creation of (i) 160,000,000 Class A Ordinary Shares; (ii) 12,000,000 convertible Class B Ordinary Shares and (iii) 8,000,000 shares of such class or classes (however designated) as the board of directors may determine in accordance with the amended and restated memorandum and articles of association of the Company, and accordingly, paragraph 8 of the Company's amended and restated memorandum of association be amended to read as follows:

"The authorised share capital of the Company is US$320,000 divided into 213,333,334 shares of US$0.0015 par value each, of which (i) 186,666,667 are designated as Class A Ordinary Shares, (ii) 15,333,333 are designated as convertible Class B Ordinary Shares and (iii) 11,333,334 shall be designated as shares of such class or classes (however designated) as the Board of Directors may determine in accordance with Article 10 of the Articles, with the power for the Company, insofar as is permitted by law and the Articles, to redeem, purchase or redesignate any of its shares and to increase or reduce the said share capital subject to the Companies Act and the Articles and to issue any part of its capital, whether original, redeemed or increased with or without any preference, priority or special privilege or subject to any postponement of rights or to any conditions or restrictions and so that unless the conditions of issue shall otherwise expressly declare every issue of shares whether declared to be preference or otherwise shall be subject to the powers hereinbefore contained."

			For			Against			Abstain
Class A Ordinary Shares			2,669,903			503,820			4,290
Class B Ordinary Shares			1,580,972			0			0
Total number of votes			4,250,875			503,820			4,290
Percentage of total votes			78.70			1.16			0.01

Proposal No. 2.

That the registered office provider of the Company be and is authorised and directed to make any necessary filings with the Registrar of Companies in the Cayman Islands in connection with the above.

			For			Against			Abstain
Class A Ordinary Shares			3,163,082			14,922			9
Class B Ordinary Shares			1,580,972			0			0
Total number of votes			4,744,054			14,922			9
Percentage of total votes			79.83		%	0.03		%	0.00		%

Exhibit no.						Description
99.1						Amended and Restated Memorandum and Articles of Association

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			Prenetics Global Limited
			By:			/s/ Lo Hoi Chun
			Name:			Lo Hoi Chun
			Title:			Chief Financial Officer
Date: August 1, 2025

FAQ

What did Prenetics (PRE) shareholders approve on 1 Aug 2025?

They approved a special resolution increasing authorised share capital to 213,333,334 shares and a related administrative filing authority.

How many additional shares can Prenetics now issue?

The company created 160 m new Class A, 12 m Class B and 8 m undesignated shares, totalling 180 m additional shares.

Was the capital increase passed by a large margin?

Yes. 4,250,875 votes (≈78.7%) were cast FOR versus 503,820 AGAINST.

Will existing Prenetics shareholders be diluted?

Potentially. The large increase suggests future equity offerings, which would lower current holders’ percentage ownership.

Did the filing include any financial results or guidance?

No. The 6-K only covered voting outcomes; no revenue, earnings or guidance figures were provided.

What is the next step after approval?

The registered office provider will file the amended Memorandum & Articles (Exhibit 99.1) with the Cayman Registrar.